The Lens Magazine, by LSI

"I think one of the reasons why they're [China] able to scale and accelerate so quickly is that there's just not as many barriers to getting data. Patient privacy is not really a thing over there" - Christopher Shen, The Lens, Vol. 2, Ed. 7 We highlighted this quote in the latest edition of The Lens because China isn’t an easy market to commercialize healthcare technologies in, especially given its strong preference for domestic innovation. Although much more complex, this quote represents just one challenge with competing in a relatively unknown market. For those building and commercializing, what are your thoughts on bringing your technology to China?

A new edition of The Lens is out now and, to our subscribers, this special edition is already on its way! This month’s cover story is a tribute to the life of Atul Butte, MD, a pioneer and advocate of data-driven innovation in healthcare. With his unfortunate passing last month, we’re highlighting Dr. Butte’s legacy of optimism, his philosophy on data and innovation, and reflections from those he impacted. “Once we let data flow, lifelong discoveries become possible.” - Dr. Atul Butte If you’d like to learn more, please send us a message or reach out to Gavin Kennedy

A $3.7B acquisition followed by a $600M acquisition, both closed within 7 months. Raymond W. Cohen played a crucial role in each and is the cover story of our latest issue of The Lens. His playbook for scaling, exiting, and winning in medtech is free for a limited time. Click here to read the full story: https://xmrrwallet.com/cmx.plnkd.in/gxhVPucR

Electrosurgical devices have been an operating room mainstay for over a century, so why are these devices experiencing accelerated growth in 2025? The answer: Surgical Robotics Learn more about our assessment into to recent developments, the competitive landscape, emerging innovations, and the data behind the market by purchasing a subscription to The Lens: https://xmrrwallet.com/cmx.plnkd.in/dZEXphUB If you missed a previous edition or want to learn more, head to our website here: https://xmrrwallet.com/cmx.plnkd.in/g7XFneau

It’s Magazine Monday! Today we’re focused on an LSI Alumni Innovator Spotlight featuring Axoft's Paul Le Floch. The Harvard University-trained materials scientist and Forbes 30 Under 30 honoree is reengineering how the brain and technology communicate, starting with a radically soft implant and a bold plan to decode the natural language of the brain. Subscribe to the newsletter for bi-monthly insights on the most important developments in Medtech, straight from The Lens Magazine, by LSI. Purchase a premium subscription to The Lens for monthly insights and thought leadership featuring top executives like Lisa Earnhardt, Gary Guthart, and Ray Cohen.

Our latest edition of The Lens features Paul Le Floch, Co-Founder and CEO of the emerging BCI company Axoft. The Harvard University-trained materials scientist and Forbes 30 Under 30 honoree is reengineering how the brain and technology communicate, starting with a radically soft implant and a bold plan to decode the natural language of the brain. Read more about Le Floch, the device mechanics, key company milestones, and the market landscape: https://xmrrwallet.com/cmx.plnkd.in/gFz2bNia Start your paid subscription today, and we’ll send you these first 8 issues to start your collection as a Day 1 reader.

Cover story feature Joe Kiani was announced as the lead investor in LSI alumni CDX Medical Technologies' $2.5M Series A funding round! CDX is looking to set a new standard in respiratory care with a next-gen ECMO platform designed for smarter delivery, easier deployment, and broader access. This funding will support the company as it advances through regulatory testing, pursues market approval, and begins commercial rollout. Kiani will also join the company’s Board of Directors, bringing strategic guidance to its next phase of growth. Congratulations to Dr. Gopal Chopra, the CDX Medical Technologies team, and Joe Kiani on this exciting milestone. You can learn more about Kiani and his philosophy on innovation here: https://xmrrwallet.com/cmx.plnkd.in/d-ug2WND

It’s a digital world, and I really do love it. But as my AI increasingly talks to your AI… the tangible moments are becoming more meaningful. I’ve been feeling it and hearing it from others too. There’s a bit of a bounceback happening: more face-to-face meetings, more time spent with things you can actually touch.  Books, magazines, real conversations. We move fast, we innovate constantly, and we rely on technology to scale everything. But I think we’re all craving a little more texture in our lives. More intentional moments. More time to think and connect without a screen. If you feel the same, consider starting a subscription to The Lens (or gift one).  We’ll send you these first 8 issues so you can start your Collection as a Day 1 reader.

Trends and data are a priority when it comes to your monthly content in The Lens, so today, let’s talk about diabetes. Along with Medtronic divesting its diabetes business into MiniMed, this is a space that’s gotten a lot of attention over the past two months. It’s an established market that’s seeing strong growth due to new developments in insulin pumps and continuous glucose monitors. Here’s the data behind the market: -- 2024 Market Size | $20.8B -- 2029 Projected Market Size | $30B+, representing a 7.6% CAGR -- 7.6% outpaces the overall medtech market (6.5%) You can get a full update on the diabetes space, sleep apnea market, Q1 earnings, and more through our most recent issue, 𝘈 𝘗𝘢𝘨𝘦 𝘧𝘳𝘰𝘮 𝘙𝘢𝘺 𝘊𝘰𝘩𝘦𝘯’𝘴 𝘗𝘭𝘢𝘺𝘣𝘰𝘰𝘬. Subscribe to The Lens for monthly, analyst-curated updates on the most important developments in medtech.

In the latest issue of The Lens, we highlighted 46 deals of new funding rounds, strategic partnerships, and M&A. Here are three that stood out and the technology behind it: Synchron - CEO | Thomas Oxley Deal Details: Strategic partnership with Apple Importance: This marks the first BCI (brain computer interface) company to achieve native integration with Apple’s BCI Human Interface Device profile. Users implanted with Synchron’s device can now control an iPhone, iPad or Vision Pro directly with their thoughts. Technology - Their neurointerventional electrophysiology (NeuroEP) platform is built on the Stentrode, an endovascular electrode array. It is designed to record or stimulate the brain from inside the blood vessels. The field of Functional Neurointervention will include brain computer interfaces, brain mapping, brain monitoring and deep brain stimulation. Synchron is working to deliver this vision over the next 10 years. Oath Surgical - CEO | Oliver Keown, MD Deal Details: Seed investment with investors including Oxford Science Enterprises, Black Opal Ventures, Rogue VC, Tau Ventures, First Spark Ventures. Importance: The company launched out of stealth mode only a few months ago and has secured $10M from seasoned investment firms. Technology: OathAI is a comprehensive operating system for surgery enabled by powerful AI technology solutions. OathAI makes surgical practice more efficient, automates administrative work, and surfaces actionable insights from clinical data across the surgical care journey, from referral to recovery. Pulnovo Medical - CEO | Jessie Lian Deal Details: ~$100M Series C including investors EQT Group and Qiming Venture Partners. Importance: With pulsed field ablation getting a lot of attention, $100M deals are still being done for radiofrequency ablation. Technology: The company is developing radiofrequency (RF) solutions for the treatment of pulmonary hypertension. PADN is a multipolar synchronous pulmonary artery RF ablation catheter that is intended to treat pulmonary hypertension by ablating the sympathetic nerve at the target site. The device is capable of point-to-point ablation of pulmonary sympathetic nerves. You can find every deal that happens in medtech on a monthly basis by subscribing to The Lens.